Clinical Trial Update: Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

View source ↗

Summary

This document reports the results of an observational study evaluating Lumigan 0.01% (bimatoprost) in patients with primary open-angle glaucoma or ocular hypert…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Lumigan (bimatoprost)

Snippet

Sponsor: Allergan | Conditions: Glaucoma, Open-Angle, Ocular Hypertension | Status: COMPLETED | Results posted: 2014-03-28